Patrick Soon-Shiong

Patrick Soon-Shiong, born on July 29, 1952, is a prominent South African and American entrepreneur, physician, and medical researcher. Renowned for his groundbreaking contributions to oncology, he is the inventor of Abraxane, a pivotal drug utilized in the treatment of lung, breast, and pancreatic cancers. In 2024, he achieved a significant milestone with the US FDA's approval of Anktiva, a novel immunotherapy drug for non-muscle invasive bladder cancer.

As the founder of NantWorks, Soon-Shiong has established a network of innovative healthcare, biotech, and artificial intelligence startups. His academic pursuits include serving as an adjunct professor of surgery and the executive director of the Wireless Health Institute at the University of California, Los Angeles. Additionally, he holds visiting professorships at prestigious institutions such as Imperial College London and Dartmouth College.

In his current role as Executive Chairman and Global Chief Medical & Technology Officer at ImmunityBio, Soon-Shiong continues to influence the medical landscape. He also chairs the Chan Soon-Shiong Family Foundation, a philanthropic organization dedicated to advancing healthcare initiatives. Since 2010, he has been a minority owner of the Los Angeles Lakers and has held the position of owner and executive chairman of the Los Angeles Times since June 2018.

With an estimated net worth of five billion six hundred million dollars, Soon-Shiong has been recognized as one of the wealthiest doctors globally and the richest man in Los Angeles. His remarkable journey reflects a commitment to innovation and philanthropy in the medical field.